Fresolimumab binds to and inhibits all isoforms of TGF-beta, utilized in trials for treating primary brain tumors, metastatic breast cancer, diffuse systemic sclerosis, malignant pleural mesothelioma, and primary focal segmental glomerulosclerosis. The DrugMonitor™ Anti-Fresolimumab Antibody (VS-1224-YC491) is an anti-drug antibody (ADA) against Fresolimumab. This drug-based antibody is raised in mice immunized with the Fresolimumab. The anti-Fresolimumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Fresolimumab in samples.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-TGFB1 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-140)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to TGF-beta. It is a human monoclonal antibody and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer (kidney cancer and melanoma).
There are currently no Customer reviews or questions for VS-1224-YC491. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.